How Long Can You Live With Congestive Heart Failure?

Survival after a congestive heart failure diagnosis varies enormously, from a couple of years in high-risk groups to well over a decade in younger patients with access to modern treatment. Large population studies have found that roughly a third of people are still alive five years after their first diagnosis, though that figure comes from data spanning decades that predate many of today’s therapies. The honest answer is that no single number captures what any individual can expect, because age, the type of heart failure, coexisting conditions, and the treatments used all push survival in different directions.

What the Population-Level Numbers Show

Two landmark studies give a sense of the broad landscape. The Framingham Heart Study, which tracked heart failure cases over several decades, found median survival after onset was about 1.7 years for men and 3.2 years for women. Five-year survival was roughly 25% for men and 38% for women.¹ The Rotterdam Study, a large European population cohort, reported five-year survival of about 35% overall, with 86% making it through the first 30 days and 63% alive at one year.²

These numbers look grim, and they are, but they reflect population averages that include many elderly patients diagnosed in an era when fewer effective treatments existed. If you are younger and diagnosed today, your personal outlook is likely better than what those older cohort studies suggest. That said, heart failure remains a serious diagnosis. The disease generally does not reverse itself, and the trend over time without intervention is progressive.

How Age and Sex Shift the Odds

Age at diagnosis is one of the strongest predictors of how long someone lives with heart failure. A study of hospital-discharged heart failure patients found that the average remaining lifespan ranged from about 19.5 years for low-risk women under 50 to roughly 2.9 years for high-risk men in their eighties.³ That gap is staggering and underscores how misleading a single average figure can be.

Women consistently live longer with heart failure than men. In a large Medicare-age study, the mortality rate for men was about 38% higher than for women after adjusting for age and race. Among women aged 67 to 74, median survival was 3.6 years; for men the same age, it ranged from about 2.3 to 2.7 years depending on race.⁴ A separate study estimated that men with heart failure lost roughly 2.4 years of life expectancy compared with their peers without the condition, while women lost about 1.6 years. Among women without other major health problems, the difference nearly vanished.⁵

Race also plays a complicated role. Among Medicare beneficiaries, Black men actually had slightly better six-year survival than white men at every age bracket, and their median survival was modestly longer (for instance, 2.7 versus 2.3 years in the 67-to-74 group). Among women, the differences by race were negligible.⁴ These patterns may reflect differences in heart failure causes and coexisting conditions rather than any inherent biological advantage.

Does Ejection Fraction Type Matter?

Heart failure comes in two major varieties. In one type, the heart muscle pumps weakly (reduced ejection fraction, sometimes called HFrEF). In the other, the heart pumps with normal strength but is too stiff to fill properly (preserved ejection fraction, or HFpEF). You might assume that having a stronger pump means a better outlook, and early research supported that intuition: annual mortality with preserved ejection fraction was about 8.7%, compared with roughly 18.9% for reduced ejection fraction in one population study.⁶

But a later population-based study following patients for five years found no significant difference in survival between the two types: about 43% alive at five years for preserved ejection fraction versus 46% for reduced ejection fraction.⁷ One reason the gap narrows over longer follow-up is that people with preserved ejection fraction tend to be older and carry more non-cardiac conditions like diabetes and kidney disease. Their hearts may pump adequately, but the burden of other illnesses eventually catches up. This is worth knowing because many patients hear “your ejection fraction is normal” and assume they are in the clear. They are not.

How Modern Medications Change the Outlook

The treatment landscape for heart failure with reduced ejection fraction has transformed over the past three decades. Today, the standard approach uses four drug classes simultaneously, and recent evidence suggests the combination can add years to life. A 2025 network meta-analysis estimated that for a representative 70-year-old patient, the standard four-drug regimen provided about 5.3 additional life-years compared with no treatment. Adding a fifth drug, vericiguat, pushed that figure to roughly 6 additional years.⁸

Those numbers are modeled projections, not direct observations from a single trial, but they represent the pooled findings of many randomized trials. The key point is that the five-year survival statistics from older cohorts, where modern drugs either did not exist or were not fully deployed, almost certainly overstate how grim things are for someone diagnosed and treated today. For heart failure with preserved ejection fraction, the drug arsenal is slimmer. SGLT2 inhibitors have shown benefit in this group, but the dramatic multi-drug survival gains are specific to reduced ejection fraction.

Implantable Devices and Their Long-Term Impact

For patients with reduced ejection fraction who remain at risk of dangerous heart rhythms, implantable cardioverter-defibrillators (ICDs) can deliver life-saving shocks. For those whose heart’s electrical system is poorly synchronized, cardiac resynchronization therapy (CRT) adds a specialized pacemaker that coordinates the heartbeat. In a large real-world registry, one- and five-year survival after ICD implantation was about 92% and 68%, respectively. For patients receiving a combined CRT-defibrillator device, those figures were 88% and 54%.⁹

Those numbers partly reflect the fact that patients who need CRT typically have more advanced disease than those who receive a standalone ICD. The survival benefit from CRT-defibrillator devices appears to hold for well over a decade. In one long-term follow-up study with nearly 14 years of median tracking, the survival advantage of CRT-defibrillator over ICD alone was sustained in patients with moderate heart failure and a widened electrical signal on their heart tracings.¹⁰ A real-world comparison found that five-year death rates were about 36% with ICD, about 42% with CRT, and roughly 68% among matched patients with no device at all.¹¹

One nuance worth understanding: as heart failure progresses, the proportion of sudden deaths that an ICD can actually prevent declines. In patients with moderate symptoms, ICDs prevent an estimated 60 to 70% of sudden deaths. But in patients with more advanced disease, that figure drops to roughly 25 to 40%, because many of the cardiac events at that stage are not the type of rhythm disturbance an ICD can fix.¹²

Heart Transplants and Mechanical Pumps

When heart failure progresses to the point that medications and devices are no longer enough, transplantation remains the gold standard. But donor hearts are scarce, and many patients are not candidates. Mechanical heart pumps, known as left ventricular assist devices (LVADs), have become a viable alternative, either as a bridge while waiting for a transplant or as a permanent solution. A meta-analysis found no significant difference in one-year mortality between transplant and LVAD, whether the pump was used as a bridge or as long-term therapy.¹³

Newer devices have continued to close the gap. A study comparing the latest-generation pump (HeartMate 3) with transplant found no statistically significant difference in three-year survival after matching patients: about 84% for the pump versus 87% for transplant. Younger patients (18 to 49) had near-identical outcomes with either approach. The main trade-off was that pump recipients were rehospitalized more often, roughly twice as frequently over three years.¹⁴

Exercise, Rehabilitation, and Self-Care

One of the most consistently supported interventions for heart failure, yet one of the most underused, is structured exercise. A joint scientific statement from the American Heart Association and American College of Cardiology noted that supervised exercise training produces large, clinically meaningful improvements in exercise capacity, symptoms, and quality of life for patients with preserved ejection fraction, comparable to or even larger than the improvements seen in reduced ejection fraction.¹⁵ Broader expert consensus holds that cardiac rehabilitation reduces heart failure hospitalizations and is safe across the spectrum of heart failure.¹⁶

Most exercise programs used in heart failure trials employ moderate-intensity endurance exercise, and improvements in peak exercise capacity on the order of 13 to 31% have been reported.¹⁷ In practical terms, that means everyday activities like climbing stairs or walking to the mailbox become noticeably less exhausting. The challenge is that fewer than a quarter of eligible heart failure patients actually get referred to or complete a formal rehabilitation program.

Sodium and Fluid Restrictions Under Scrutiny

If you have heart failure, you have almost certainly been told to cut salt and limit fluids. The evidence behind those recommendations is thinner than most people realize. A meta-analysis of randomized trials found that sodium restriction did not reduce the risk of death, hospitalization, or the combination of the two.¹⁸ That does not mean salt is harmless, but it does mean the aggressive low-sodium diets many patients are prescribed lack solid backing from controlled studies.

Fluid restriction is similarly uncertain. While some pooled analyses have suggested a benefit, methodological concerns weakened the conclusions.¹⁹ A recent randomized trial comparing liberal versus restricted fluid intake found no significant differences in death, hospitalization, or diuretic use between the two groups, though the study was small and safety events were few overall.²⁰ The bottom line is that if rigid fluid or sodium limits are making your life miserable, that is a conversation worth having with your cardiologist, because the hard data supporting those restrictions is weaker than the certainty with which they are typically prescribed.

Hospitalizations and How They Cluster

Heart failure is the leading cause of hospitalization in older adults, and the pattern of those admissions matters for prognosis. In a cohort study tracking patients over their remaining lifetimes, 10-year mortality was nearly 99%. But the hospitalizations were not spread evenly. About 27% of all heart failure readmissions happened in the first tenth of a patient’s survival period (the weeks and months right after an initial discharge), and roughly 40% occurred in the last tenth (the period just before death).²¹ In other words, there is often a relatively stable middle period between two danger zones. If you can get through the first few months after an initial hospitalization without a readmission, you are statistically on firmer ground.

A prior heart failure hospitalization is itself a risk factor for dying sooner. Among the cardiovascular comorbidities most strongly linked to long-term death in one large Australian and New Zealand registry, a history of previous heart failure topped the list, followed by valvular heart disease and vascular disease.²²

The Kidney Connection

Heart failure and kidney disease feed on each other in a cycle that cardiologists call cardiorenal syndrome. The heart’s inability to pump effectively reduces blood flow to the kidneys, and failing kidneys cause fluid overload that further strains the heart. Pre-existing chronic kidney disease is common in heart failure patients and contributes to worse outcomes during acute episodes.²³ Kidney function is factored into nearly every risk-prediction score for heart failure, and for good reason: it is one of the strongest modifiable markers of how someone will do.²⁴ If your kidney function is declining alongside your heart failure, the medical team will typically pay aggressive attention to medications and fluid balance to try to slow the spiral.

The Obesity Paradox

In most diseases, carrying excess weight is associated with worse outcomes. Heart failure flips that relationship. Multiple studies have found that overweight patients with heart failure actually live longer than lean ones, a pattern known as the obesity paradox. A large retrospective study found that overweight patients without diabetes had the most favorable outcome profile, while lean patients with diabetes had the worst. After adjusting for other factors, overweight diabetic patients still had a roughly 35% lower one-year mortality risk compared with lean diabetic patients.²⁵

The picture gets more complicated when diabetes enters the equation. A European study found that the obesity paradox held clearly for non-diabetic heart failure patients: being underweight roughly doubled the risk of death while obesity lowered it. But for patients with type 2 diabetes, the protective effect of higher weight disappeared entirely.²⁶ The reason remains debated. One theory is that metabolic disturbances in diabetes override whatever physiological reserve extra weight provides. Regardless, the practical takeaway is that aggressive weight loss in a heart failure patient should be guided by a clinician, not assumed to be beneficial.

Social and Economic Factors

Your zip code and income bracket influence your heart failure prognosis more than many patients realize. In a large cohort study, lower family income was associated with a 56% higher rate of cardiovascular death compared with higher income, and lower educational attainment was independently linked to increased rates of heart attacks.²⁷ A U.S.-based analysis found that unemployment, poverty, food insecurity, lack of insurance, and low education were all independently associated with higher mortality in people with heart failure. The effect was especially stark for adults under 65: the combination of heart failure and social disadvantage was associated with roughly eight times higher all-cause mortality and ten times higher cardiovascular mortality compared with advantaged peers.²⁸

These are not just correlations waiting for a more sophisticated analysis to explain away. People with fewer resources have less access to cardiology specialists, skip medications because of cost, miss follow-up appointments, eat less healthily, and live in environments with higher stress. Heart failure is one of those conditions where consistent, careful self-management and prompt medical attention for symptom changes make a measurable difference, and both of those things are harder to do when you are struggling economically.

Remote Monitoring and Telehealth

Keeping heart failure patients connected to their care team between clinic visits is a growing focus. A meta-analysis of telehealth strategies found that remote monitoring reduced both one-year mortality and rehospitalization rates compared with standard care.²⁹ These programs typically involve daily weight checks, blood pressure measurements, and symptom questionnaires transmitted to a nurse or care coordinator who can flag problems early. The benefit is most obvious in the high-risk window right after a hospitalization, when the probability of readmission is highest.

When Genetics Drive the Prognosis

Not all heart failure starts the same way, and the underlying cause matters for long-term outlook. In dilated cardiomyopathy, a form of heart failure where the heart muscle stretches and weakens, genetic testing is increasingly used to guide prognosis and treatment. A large study using a genotype-first approach found that variants in certain genes were the strongest predictors of outcome. Mutations in LMNA, FLNC, and BAG3 carried the highest risk for both progressive heart failure and dangerous heart rhythm problems.³⁰ Patients with LMNA mutations, for instance, are often fast-tracked for ICD implantation even before their ejection fraction drops to a level that would normally trigger the recommendation. The growing role of genetic testing means that two patients with apparently identical clinical profiles can have very different predicted trajectories based on what is happening at the molecular level.

Palliative Care Is Not Just for the End

Many people hear “palliative care” and think “giving up.” That is a misconception worth correcting. Palliative care is a specialized approach to managing symptoms and supporting decision-making that can run alongside active treatment, not just at the end of life. Among the most common symptoms in advanced heart failure are breathlessness, fatigue, pain, loss of appetite, and depression.³¹ A review of studies evaluating palliative care in heart failure found that most reported statistically significant improvements in quality of life, reduced symptom burden, and improved emotional well-being, including depression and anxiety.³²

Palliative care teams also help navigate difficult conversations about advance directives, when to deactivate an ICD, and what the realistic goals of further treatment are. Cognitive impairment is common in heart failure patients and can make medication adherence and self-care harder, which adds another layer of complexity to decision-making.³³ Early integration of palliative care, ideally before the disease reaches its final stages, gives patients and families more time and more information to make choices that align with their values.